Literature DB >> 21039723

Elevated anti-Müllerian hormone (AMH) and inhibin B levels in prepubertal girls with type 1 diabetes mellitus.

Ethel Codner1, Germán Iñiguez, Isabel M Hernández, Patricia Lopez, Hana K Rhumie, Claudio Villarroel, Rodolfo A Rey.   

Abstract

OBJECTIVE: Elevated anti-Müllerian hormone (AMH) and adrenal androgen levels have been observed during childhood in girls at risk of developing polycystic ovarian syndrome (PCOS). The aim of this study was to evaluate ovarian function and adrenal steroid levels in prepubertal girls with type 1 diabetes mellitus (T1D).
DESIGN: Cross-sectional study. PATIENTS/MEASUREMENTS: We evaluated hormonal and ultrasonographic characteristics in girls with T1D (N = 73) and compared them to characteristics found in a control group of healthy girls (N = 86). Data are reported as geometric means (95% CI).
RESULTS: Prepubertal girls with T1D had higher levels of AMH (29·1 pmol/l (23·2-36·3) vs 20·9 pmol/l (16·6-26·1), P = 0·038), inhibin B (arithmetic mean: 16·7 pg/ml (11·6-21·7) vs 11·7 pg/ml (10·0-13·5), P = 0·044) and dehydroepiandrosterone sulphate (DHEAS) (0·3 nmol/l (0·2-0·6) vs 0·2 nmol/l (0·1-0·3)) than controls (P = 0·045). During puberty, decreasing AMH levels were observed in girls with T1D only (P < 0·0001). Girls with T1D in Tanner stages 4-5 had lower AMH levels than their paired healthy controls (10·1 pmol/l (7·4-13·9) vs 15·7 pmol/l (11·6-21·3), respectively, P = 0·047).
CONCLUSIONS: Our observations indicate that prepubertal girls with T1D may exhibit similar endocrine findings to those of other girls at risk of developing PCOS. The elevated levels of AMH and inhibin B suggest that higher numbers of follicles are present in the ovary during childhood in these patients and that insulin treatment may act as a local growth factor. In addition, AMH levels differed in prepubertal and pubertal girls, suggesting that the effect of T1D on ovarian folliculogenesis changes once gonadotrophin levels rise during puberty.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21039723     DOI: 10.1111/j.1365-2265.2010.03887.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  6 in total

1.  Reproductive endocrinology: Diabetes, puberty and pcoS risk.

Authors:  Rosanne Diaz
Journal:  Nat Rev Endocrinol       Date:  2011-01       Impact factor: 43.330

2.  Increased androgen, anti-Müllerian hormone, and sporadic anovulation in healthy, eumenorrheic women: a mild PCOS-like phenotype?

Authors:  Lindsey A Sjaarda; Sunni L Mumford; Kerri Kissell; Karen C Schliep; Ahmad O Hammoud; Neil J Perkins; Jennifer Weck; Jean Wactawski-Wende; Enrique F Schisterman
Journal:  J Clin Endocrinol Metab       Date:  2014-02-28       Impact factor: 5.958

Review 3.  The ageing ovary and uterus: new biological insights.

Authors:  S M Nelson; E E Telfer; R A Anderson
Journal:  Hum Reprod Update       Date:  2012-10-26       Impact factor: 15.610

4.  Effect of glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort.

Authors:  Catherine Kim; Patricia A Cleary; Catherine C Cowie; Barbara H Braffett; Rodney L Dunn; Mary E Larkin; Patricia M Gatcomb; Hunter B Wessells; David M Nathan; Aruna V Sarma
Journal:  Diabetes Care       Date:  2013-10-29       Impact factor: 19.112

5.  Antimüllerian Hormone Levels of Infants with Premature Thelarche

Authors:  Nursel Muratoğlu Şahin; Elvan Bayramoğlu; Hatice Nursun Özcan; Erdal Kurnaz; Melikşah Keskin; Şenay Savaş-Erdeve; Semra Çetinkaya; Zehra Aycan
Journal:  J Clin Res Pediatr Endocrinol       Date:  2019-03-12

6.  Anti-müllerian hormone is not associated with cardiometabolic risk factors in adolescent females.

Authors:  Emma L Anderson; Abigail Fraser; William McNally; Naveed Sattar; Hany Lashen; Richard Fleming; Scott M Nelson; Debbie A Lawlor
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.